

## OCULAR DISORDERS IN PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, NIGERIA

\*A. I. Osahon, \*\*A. N. Onunu

*Departments of \*Ophthalmology and \*\*Medicine, University of Benin Teaching Hospital Benin City Nigeria*

### ABSTRACT

**Aims:** Ocular diseases occur at all stages of HIV infection. Reports have documented that the prevalence of these diseases vary from region to region. Thus the objective of this study is to determine the prevalence of these ocular disorders among people infected with HIV at the University of Benin Teaching Hospital, Benin City, Nigeria

**Methods:** The study was prospective in design and all patients who tested positive for HIV antibodies over a 5-year period from September 1997 to August 2002 in Dermatology and Ophthalmology Units at the University of Benin Teaching Hospital (UBTH), Benin City, Nigeria, were examined for the presence of ocular disease.

**Results:** Twenty-one of the 526 HIV-positive patients had ocular disease, giving a prevalence rate of 4.0%. Their mean age was  $39.5 \pm 10.5$  years. Fourteen patients (2.7%) had Herpes zoster ophthalmicus, four (0.8%) had Squamous cell carcinoma, two (0.4%) had Kaposi's sarcoma while one (0.2%) had Cytomegalovirus retinitis. The signs seen on ocular examination were vesicular rash (66.7%) diminished vision (57.1%) corneal ulcers (38.0%), conjunctival injection (38.0%), and eyelid nodules (28.6%), preauricular lymphadenopathy (28.6%), purulent eye discharge (19.0%), conjunctival nodules (9.5%), papilledema (9.5%), ptosis (9.5%), sudden visual loss in both eyes (9.5%), pupillary dilatation (4.8%), chemosis (4.8%), uveitis (4.8%), and retinal hemorrhage (4.8%).

**Conclusions:** In this study the prevalence of ocular disorders was 4.0% in the 526 HIV-positive patients studied. Herpes zoster ophthalmicus was the commonest ocular disease encountered, occurring in 2.7% of the study population. This is in keeping with reports from other parts of the world. We recommend that young patients presenting with Herpes zoster ophthalmicus, conjunctival Squamous cell carcinoma and sudden onset bilateral blindness should be screened for HIV infection.

**Key words:** Ocular Disorders, HIV infection, University of Benin Teaching Hospital, Benin City. (Accepted 26 January 2007)

### INTRODUCTION

The prevalence of Human Immunodeficiency virus (HIV) infection in Nigeria is currently estimated at 5.8%.<sup>1</sup> Current Worldwide estimates put the number of people already infected by HIV at 36.1 million, with the majority of these people living in Sub-Saharan Africa<sup>2,3</sup>. Heterosexual transmission is the main mode of spread of the virus in Saharan Africa, where high transmission rates are associated with a high prevalence of other sexually transmitted diseases and casual unprotected sex with multiple partners<sup>1,3</sup>. There is a wide spectrum of Ocular disorders encountered in people who are infected with HIV.

These include opportunistic and non-opportunistic infections of the eyes, HIV-related retinopathy, tumors and cutaneous hypersensitivity reactions<sup>4,6</sup>. The prevalence of these ocular diseases seems to differ in the various regions of the World<sup>5-15</sup>. There had been reports on the ocular diseases associated with HIV in Nigeria<sup>8,9,15</sup>, but these were mainly case reports. Thus the objective of this study is to document the pattern and prevalence of ocular diseases in persons infected by the Human Immunodeficiency virus at the University of Benin Teaching Hospital, Benin City, Nigeria.

### PATIENTS AND METHODS

All patients presenting to the Dermatology/Infectious diseases and Ophthalmology Units at the University

---

Correspondence: Dr A. I. Osahon  
E-Mail: osahonai@yahoo.com

of Benin Teaching Hospital (UBTH), Benin City from September 1997 to August 2002, who were positive for HIV antibodies were recruited into the prospective study. These patients presented to the hospital first either at the Ophthalmology (because of Eye disease) or Dermatology clinics (because of skin rash on the face) and were subsequently managed jointly by both units. Each study subject was interviewed after consent was obtained from them to get details of the clinical history, epidemiological data and social history. A thorough physical examination including examination of the eyes by an ophthalmologist was conducted. Those with Ocular symptoms and signs were further examined by special tests. Examination of the Eyes included tests for visual acuity for near and distant vision, slit-lamp biomicroscopy, direct and binocular indirect ophthalmoscopy and intraocular pressure measured with Goldman appplanation Tonometer attached to the slit-lamp. Fluorescein angiography and fundal photography were not done because these facilities were not available at our center. The screening for HIV antibodies was done using Wellcozyme Kits (Wellcome Laboratory, Dartford, England) and Rapid assay Kits- Immunocomb HIV 1 & 2 Bispot (PBS Organics, Cedex, France). Confirmation was by using the double test algorithm.

## RESULTS

A total of 526 patients who tested positive for HIV antibodies were seen during the 6-year study period. Twenty-one of these patients had ocular diseases giving prevalence rate of 4.0 percent (4.0%). The mean age of patients with ocular disease is  $39.5 \pm 10.5$  years. There were 10 male (47.6%) and 11 female (52.4%) patients giving a male to female sex ratio of 1 to 1.1 (Table 1)

The ocular diseases encountered in these patients includes fourteen patients (2.7%) with Herpes Zoster ophthalmicus, four (0.8%) with Squamous cell carcinoma two (0.4%) with Kaposi's sarcoma involving the eyelids and conjunctiva and one patient (0.2%) with cytomegalovirus induced Retinitis (Table 2) The presenting symptoms in these patients were vesicular rash (66.7%), ocular pruritus (66.7%), headache (66.7%), hemi-facial pain (57.1%), deteriorating vision (57.7%) redness of Eye (38.0%), nodular lesions in the eyelids and eyes (28.6%). Other symptoms encountered were excessive tearing (28.6%), weakness (23.8%), fever (19.0%), insomnia (19.0%) and total loss of vision (9.5%). (Table 3)

The signs encountered in them during physical examination were vesicular rash (66.7%), various

degrees of visual impairment visual acuity of between 6/18 and 6/60, (57.1%), corneal ulcer (38.0%), corneal edema (38.0%) conjunctival injection (38.0%) eyelid nodules (28.6%) lymphadenopathy (28.6%) purulent eye discharge (19.0%), conjunctival nodules (9.5%), papilledema (9.5%) ptosis (9.5%), complete visual loss i.e no light perception (9.5%) pupillary dilatation (4.0%), chemosis (4.8%), uveitis (4.0%) and retinal hemorrhages (4.8%). (Table 4) of the 2 patients who had complete visual loss (no light perception). One had Cytomegalovirus retinitis and the other had perforated herpetic corneal ulcer.

**Table 1: Age and Sex Distribution of Patients with ocular disease**

Age Range (Years)	Gender		Total (%)
	Male	Female	
20 29	1	3	4(19.0)
30 40	2	3	6(28.6)
40 49	3	2	6 (28.6)
50 59	4	3	5(23.8)
<b>TOTAL</b>	<b>10(47.6)</b>	<b>11(52.4)</b>	<b>21(100.0)</b>

**Table 2: Ocular Disorders in HIV Disease in Benin City, Nigeria**

**Table 2: Ocular Disorders in HIV Disease in Benin City, Nigeria**

Diseases	Frequency *(n = 526)	%
Herpes Zoster Ophthalmicus	14	2.7%
Squamous Cell Carcinoma	4	0.8%
Kaposi's Sarcoma	2	0.4%
**CMV Retinitis	1	0.2%
<b>TOTAL</b>	<b>21</b>	<b>(4.0%)</b>

\* n = 526; Total number of Patients examined

\*\* Cytomegalovirus (CMV) induced retinitis

**Table 3: Symptoms in Patients with ocular disease**

Symptom	Frequency *(n=21)	%
Vesicular Rash	14	66.7
Ocular pruritus	14	66.7
Headache	14	66.7
Hemifacial pain	12	57.1
Deteriorating vision	12	57.1
Redness of Eye	8	38.0
Nodular Lesions in	6	28.6
Eyes/Eyelids	6	28.6
Excessive Tearing	5	23.8
Weakness	4	19.0
Fever	4	19.0
Insomnia	2	9.5
Complete visual loss (No light perception)		

\*Total number of patients with ocular disease

**Table 4: Signs in Patients with Ocular**

Sign	Frequency *(n=21)	%
Vesicular rash	14	66.7
Incomplete visual loss	12	57.1
Corneal ulcer	8	38.0
Corneal edema	8	38.0
Conjunctival injection	8	38.0
Eyelid nodules	6	28.6
Lymphadenopathy	6	28.6
Purulent discharge	4	19.0
Conjunctival nodules	2	9.5
Papilledema	2	9.5
Ptosis	2	9.5
Complete visual loss (No light perception)	2	9.5
Pupillary dilatation	1	4.8
Uveitis	1	4.8
Chemosis	1	4.8
Retinal Haemorrhage	1	4.8

Total number of patients with ocular disease = 21

Note: Many patients had more than one ocular problem.

## DISCUSSION

Ocular diseases occur at all stages of HIV infection<sup>5,6,11-13</sup>. In this series the prevalence of ocular disorders was 4.0% in the 526 HIV-positive patients studied. Herpes Zoster ophthalmicus was the commonest ocular disease encountered, occurring in 2.7% of the study population. This is in keeping with reports from other parts of the world prevalence Of Herpes

Zoster ophthalmicus in HIV infected people had been reported to be up to 10%<sup>5,11-13</sup>. The disease tends to run a more severe course in these patients with corneal involvement severe scarring of the Eyelids and post herpetic Neuralgia<sup>11,12</sup>. Herpes Zoster is a non-opportunistic infection and can occur at any stage of HIV infection, sometimes its occurrence is the first indication of the presence of HIV infection. This is in keeping with two previous reports from Nigeria<sup>8,9</sup> on HIV infection and Herpes zoster ophthalmicus. Herpes Zoster ophthalmicus in the young is a marker for HIV infection in Africa with a high positive predictive value<sup>13</sup>, our findings in this study are in agreement with this statement because most of our patients were young with a mean age of  $39.5 \pm 10.5$  years. In this series, Herpes simplex virus keratitis was not a major problem among our patients seropositive for HIV, which is in agreement with findings from elsewhere<sup>14</sup> and in Nigeria<sup>15</sup>. Unlike the findings of Akinsola et al<sup>15</sup> from Lagos, Nigeria, who did not record any case of Squamous cell carcinoma of the conjunctiva in their 12-month study, four (0.8%) of our patients had Squamous cell carcinoma of the conjunctiva. These patients were all under 40 years of age and had very aggressive disease. Squamous cell carcinoma of the conjunctiva is the most common malignant conjunctival neoplasm in patients infected by HIV<sup>16</sup>. As clinicians become more aware of this relationship; we believe more cases would be identified. Traditionally, the risk factors for Squamous cell carcinoma of the conjunctiva include excessive exposure to ultraviolet light<sup>17,18</sup> exposure to petroleum products, heavy cigarette smoking, light hair and ocular pigmentation,<sup>18,19</sup> family origin in the British Isles, Austria or Switzerland,<sup>19</sup> and Human papilloma virus (HPV) infection.<sup>20,21</sup> In addition to these, Human Immunodeficiency viral infection has become an important risk factor for Squamous cell carcinoma of the conjunctiva especially when it occurs in the younger age group.

In this study we found only one case (0.2%) of cytomegalovirus (CMV) induced retinitis. This is in keeping with reports from other studies that the frequency of cytomegalovirus (CMV) induced retinitis seems to be much lower in Sub-Saharan Africa<sup>6,7</sup> than in Europe or North America. The shorter life expectancy of patients infected with HIV in developing countries probably reduces the period of profound immunodeficiency during which patients are likely to develop cytomegalovirus (CMV) induced retinitis.

## RECOMMENDATIONS

In view of the results obtained in this study we recommend that young patients presenting with Herpes zoster ophthalmicus, conjunctival Squamous cell carcinoma and sudden onset bilateral blindness should be screened for HIV infection, because these might be markers to the presence of HIV infection. This will allow for early detection and commencement of treatment before severe immunodeficiency develops.

## REFERENCES

1. Joint United Nation Programme on HIV/AIDS. Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections Nigeria, 2001 Update (revised). Geneva, Switzerland: UNAIDS/WHO, 2001.
2. **Piot P, Bartos M, Ghys PD, Walker N, Schwartzamder B.** The global impact of HIV/AIDS. *Nature* 2001; 410: 968-73
3. Joint United Nations Program on HIV/AIDS. Report on the HIV/AIDS global epidemic- June 2000. Geneva, Switzerland: Joint United Nation Program on HIV/AIDS, 2000, UNAIDS/00.13E.
4. **Kestelyn P, Lewallen S.** Ocular problems with HIV infection and AIDS in Africa. *Community Eye Health*, 1995; 8: 20-23.
5. **Holland GN, Pepose JS, Petit TH, Gottlieb MS, Yee RD, Foos RY.** Acquired Immune deficiency Syndrome. Ocular manifestations. *Ophthalmology* 1983; 90: 859- 873.
6. **Kestelyn PH Van de Perre Ph, Rowroy D, Lepage Ph, Bogaerts J, Nzaramba D, Clumeck C.** A prospective Study of the ophthalmic findings in the acquired immune deficiency syndrome. *Am J. Ophthmol.* 19985; 100: 230-238.
7. **Lightman S.** HIV/AIDS: The differing ocular manifestations in Developed and Developing Countries *Community Eye Health*. 1995 (8)(16): 17-18.
8. **Nwosu SNN, Anyiwo CE, Nwosu MC.** Herpes Zoster Ophthalmicus associated with HIV infection: A report of two cases. *Nig. Med. J.* 1995; 28(1): 27-29.
9. **Osahon AI.** HIV infection and Herpes Zoster Ophthalmicus; UBTH Eye Clinic experience (Initial observation). *Nig. J. Ophthalmol.* 1999; 7(1):1-4.
10. WHO global programme on AIDS. Operatonal characteristics on commercially available assays to detect antibodies to HIV-1 and/or HIV-2 in human sera. Report 4, Geneva: WHO; 1991, 5
11. **Restegly PN Sevens AM Bakkers E, Rouvroy D, Van de Peery PH.** Severe Herpes Zoster ophthalmicus in young African patients: a marker for HTLV-III seropositivity. *Br. J. Ophthalmol* 1987; 71: 806-809.
12. **Lewallen S.** Herpes Zoster ophthalmicus in Malawi. *Ophthalmology* 1994; 101: 1801-1804.
13. **Van De Perre P, Bakkers E, Batungwanayo J, Kestelyn P, Lepage P, Nzarama D, Bogaerts J, Seruflora a, Rouvroy D, Uwimana A, Butzler JP.** Herpes Zoster in African Patients: An early manifesation of HIV infection. *Scand J. Infect. Dis.* 1988; 20: 277 -282.
14. **William G, Hodge WG, Todd P, Margolis TP.** Herpes simplex keratitis among patients who are positive or negative for Human immunodeficiency virus: An epidemiological study. *Ophthalmology* 1997; 104: 120 -4.
15. **Akinsola FB, Okanni CC, Majekodunmi AA, Akinsete I.** Ocular manifestation of HIV in Lagos Lagos University Teaching Hospital experience. *Nig. Postgrad. Med. J.* 1996; 4: 84 - 87.
16. **Kim PY, Seiff SR, Howes EL, O'Donnell JJ.** Necrotising scleritis secondary to conjunctival squamous cell carcinoma in acquired immune deficiency syndrome. *Am J. Ophthalmol.* 1990; 109: 231 32.
17. **Rodriguez-Sains RS.** Ophthalmologic oncology: Common conjunctival neoplasms. *J. Dermatol. Surg. Oncol.* 1981; 7: 195 -99.
18. **Lee GA, Williams G, Hirst LW, Green AC.** Risk factors in the development of ocular surface epithelial dysplasia. *Ophthalmology.* 1994; 101: 360 -64.
19. **Napora C, Cohen EJ, Genvert GI, Presson AC, Arentsen JJ, Eagle RC et al.** Factors associated with conjunctival intraepithelial neoplasm: a case control study. *Ophthalmic Surg.* 1990; 21: 27 30.
20. **McDonnell JM, McDonnell PJ, Sun YY.** Human papilloma virus DNA in tissues and ocular surface swabs of patients with conjunctival epithelial neoplasm. *Invest. Ophthalmol. Vis. Sci.* 1992; 33: 184 89.
21. **Odrich MG, Jakobiec FA, Lancaster WD, Kenyon KR, Kelly LD, KommehI EW et al.** A spectrum of bilateral squamous conjunctival tumours associated with Human papilloma virus type 16. *Ophthalmology.* 1991; 98: 628 -635.